Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Collegium Pharmaceutical, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 GENERATED RECORD QUARTERLY NET REVENUE OF $188.0 MILLION, UP 29% YEAR-OVER-YEAR   GENERATED RECORD QUARTERLY JORNAY PM  NET REVENUE OF$32.6 MILLION AND GREW PRESCRIPTIONS BY 23% YEAR-OVER-YEAR   GENERATED NET REVENUE OF$155.4 MILLIONFROM THE PAIN PORTFOLIO, UP 7% YEAR-OVER-YEAR WITH ALL THREE CORE PRODUCTS RECORDING REVENUE GROWTH IN THE QUARTER   RAISED FULL-YEAR 2025 NET REVENUE GUIDANCE TO BE IN THE RANGE OF $745 TO $760 MILLION AND ADJUSTED EBITDA GUIDANCE IN THE RANGE OF $440 TO $455 MILLION   ENDED Q2'25 WITH CASH,CASH EQUIVALENTS AND MARKETABLE SECURITIESOF$222.2 MILLION   BOARD OF DIRECTORS AUTHORIZED $150 MILLION SHARE REPURCHASE PROGRAM   CONFERENCE CALL SCHEDULED FOR TODAY AT 8:00 A.M. ET  STOUGHTON, MASS.

COLLEGIUM REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS; RAISES 2025 OUTLOOK

STOUGHTON, MASS., JULY 24, 2025 (GLOBE NEWSWIRE) -- COLLEGIUM PHARMACEUTICAL, INC.(NASDAQ: COLL) TODAY ANNOUNCED THAT IT WILL REPORT SECOND QUARTER 2025 FINANCIAL RESULTS BEFORE THE MARKET OPENS ONTHURSDAY, AUGUST 7, 2025. FOLLOWING THE RELEASE OF THE FINANCIALS, THE COMPANY WILL HOST A LIVE CONFERENCE CALL AND WEBCAST AT8:00 A.M. ET.

COLLEGIUM TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON AUGUST 7, 2025

STOUGHTON, MASS., JULY 07, 2025 (GLOBE NEWSWIRE) -- COLLEGIUM PHARMACEUTICAL, INC.(NASDAQ: COLL), A LEADING, DIVERSIFIED BIOPHARMACEUTICAL COMPANY COMMITTED TO IMPROVING THE LIVES OF PEOPLE LIVING WITH SERIOUS MEDICAL CONDITIONS, TODAY ANNOUNCED ITS BOARD OF DIRECTORS HAS AUTHORIZED A NEW SHARE REPURCHASE PROGRAM TO REPURCHASE UP TO$150 MILLIONIN COMMON STOCK THROUGH DECEMBER 31, 2026.

COLLEGIUM ANNOUNCES $150 MILLION SHARE REPURCHASE PROGRAM

STOUGHTON, MASS., MAY 19, 2025 (GLOBE NEWSWIRE) -- COLLEGIUM PHARMACEUTICAL, INC.(NASDAQ: COLL) TODAY ANNOUNCED THAT ITS MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES:

COLLEGIUM TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

STOUGHTON, MASS., MAY 12, 2025 (GLOBE NEWSWIRE) -- COLLEGIUM PHARMACEUTICAL, INC.(NASDAQ: COLL), A LEADING, DIVERSIFIED BIOPHARMACEUTICAL COMPANY COMMITTED TO IMPROVING THE LIVES OF PEOPLE LIVING WITH SERIOUS MEDICAL CONDITIONS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO AN ACCELERATED SHARE REPURCHASE ("ASR") AGREEMENT WITH JEFFERIES LLC TO REPURCHASE $25 MILLION OF THE COMPANY'S COMMON STOCK. COLLEGIUM WILL EXECUTE THE ASR AS PART OF THE $150 MILLION SHARE REPURCHASE PROGRAM AUTHORIZED BY ITS BOARD OF DIRECTORS IN JANUARY 2024. UPON COMPLETION OF THIS ASR, COLLEGIUM WILL HAVE $65 MILLION REMAINING UNDER THE PROGRAM.

COLLEGIUM ANNOUNCES $25 MILLION ACCELERATED SHARE REPURCHASE PROGRAM

 GENERATED Q1'25 QUARTERLY NET REVENUE OF $177.8 MILLION, UP 23% YEAR-OVER-YEAR   GREW JORNAY PM  PRESCRIPTIONS BY 24% YEAR-OVER-YEAR AND REPORTED QUARTERLY NET REVENUE OF $28.5 MILLION; JORNAY PM PRESCRIBERS REACHED AN ALL-TIME-HIGH   COMPLETED JORNAY PM FIELD FORCE EXPANSION   GENERATED NET REVENUE OF $149.2 MILLION FROM THE PAIN PORTFOLIO, UP 3% YEAR-OVER-YEAR WITH ALL THREE CORE PRODUCTS RECORDING REVENUE GROWTH IN THE QUARTER   ENDED Q1'25 WITH CASH,CASH EQUIVALENTS AND MARKETABLE SECURITIESOF$197.8 MILLION   BOARD OF DIRECTORS AUTHORIZED $25.0 MILLION ACCELERATED SHARE REPURCHASE PROGRAM   REAFFIRMED FULL-YEAR 2025 GUIDANCE   CONFERENCE CALL SCHEDULED FOR TODAY AT 4:30 P.M. ET  STOUGHTON, MASS.

COLLEGIUM REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS

STOUGHTON, MASS., APRIL 24, 2025 (GLOBE NEWSWIRE) -- COLLEGIUM PHARMACEUTICAL, INC.(NASDAQ: COLL) TODAY ANNOUNCED THAT IT WILL REPORT FIRST QUARTER 2025 FINANCIAL RESULTS AFTER THE MARKET CLOSES ONTHURSDAY, MAY 8, 2025.

COLLEGIUM TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS ON MAY 8, 2025

STOUGHTON, MASS., APRIL 01, 2025 (GLOBE NEWSWIRE) -- COLLEGIUM PHARMACEUTICAL, INC.(NASDAQ: COLL) TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 24TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE BEING HELD VIRTUALLY FROM APRIL 7-10, 2025.

COLLEGIUM TO PARTICIPATE IN 24TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

STOUGHTON, MASS., MARCH 27, 2025 (GLOBE NEWSWIRE) -- COLLEGIUM PHARMACEUTICAL, INC. (NASDAQ: COLL) TODAY ANNOUNCED IT WILL PRESENT FOUR POSTERS HIGHLIGHTING REAL-WORLD PATIENT DATA FROM ITS DIFFERENTIATED PAIN PORTFOLIO AT PAINCONNECT 2025, THE AMERICAN ACADEMY OF PAIN MEDICINE (AAPM)'S ANNUAL MEETING, BEING HELD IN AUSTIN, TX, FROM APRIL 3-6, 2025.

COLLEGIUM TO PRESENT REAL-WORLD DATA AT PAINCONNECT 2025, THE AMERICAN ACADEMY OF PAIN MEDICINE'S ANNUAL MEETING

GINO SANTINI APPOINTED AS CHAIRMAN OF THE BOARD, MICHAEL HEFFERNAN, FOUNDER AND CHAIRMAN AND GWEN A. MELINCOFF, BOARD MEMBER TO RETIRE FROM BOARD 

Collegium Pharmaceutical, Inc.

COLL

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Collegium Pharmaceutical, Inc.

COLL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

COLL